Related Experiment Video
Updated: May 21, 2025

06:11
A Conflict Model of Reward-seeking Behavior in Male Rats
Published on: February 20, 2019
7.3K
Neural Correlates of Opioid-Induced Risk-Taking Behavior in the Prelimbic Prefrontal Cortex.
Cana B Quave1,2, Andres M Vasquez1,3, Guillermo Aquino-Miranda1
1Department of Neurobiology & Anatomy, The University of Texas Health Science Center, Houston, Texas 77030.
Summary
Researchers studied risky opioid seeking in rats using a novel approach-avoidance task. Persistent prelimbic cortex inhibitory signaling in drug-associated contexts correlates with increased risk-taking behavior in opioid use disorder.
Area of Science:
- Neuroscience
- Behavioral Neuroscience
- Addiction Research
Background:
- Opioid use disorder is characterized by impaired decision-making and risky behaviors.
- The neural mechanisms driving risky opioid seeking remain unclear.
- The prefrontal cortex plays a crucial role in executive functions and decision-making.
Purpose of the Study:
- To investigate the neural correlates of risky opioid seeking in the prelimbic cortex (PL) using a novel approach-avoidance conflict task.
- To examine how PL neuronal activity changes in response to opioid cues and motivational conflict.
- To identify neural signatures associated with different risk-taking behaviors in an opioid use disorder model.
Main Methods:
- Developed a modified conditioned place preference task incorporating an approach-avoidance conflict (cat odor threat).
- Utilized K-means clustering to categorize rats into 'Risk-Takers' and 'Risk-Avoiders' based on behavior.
- Performed single-unit recordings in the prelimbic cortex (PL) during behavioral tasks following acute and repeated morphine administration.
Main Results:
- Morphine exposure initially suppressed PL neuronal activity, an effect diminished after repeated administration.
- Risk-Avoiders showed persistent post-morphine excitation in PL across conditioning.
- Persistent inhibition of PL activity during the conflict test was observed specifically in Risk-Takers, alongside increased location-specific firing.
Conclusions:
- Persistent inhibitory signaling in the PL within drug-associated contexts during motivational conflict may drive risk-taking behavior in opioid use disorder.
- The prelimbic cortex is a critical region for understanding drug-environment interactions and risky opioid use.
- Findings refine a preclinical addiction model and highlight the prefrontal cortex for translational studies on risky opioid use.
Related Concept Videos
Drug Abuse and Addiction: Pharmacological Phenomena
419
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
419
Analgesia and Pain Management
415
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
415
Opioid Receptors: Overview
413
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
413

